Regeneron Pharmaceuticals Stock Price, News & Analysis (NASDAQ:REGN)

$371.53 0.25 (0.07 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$371.53
Today's Range$370.96 - $376.47
52-Week Range$340.09 - $543.55
Volume662,124 shs
Average Volume660,649 shs
Market Capitalization$39.92 billion
P/E Ratio33.74
Dividend YieldN/A
Beta1.52

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:REGN
CUSIP75886F10
Phone+1-914-3477000

Debt

Debt-to-Equity Ratio0.12%
Current Ratio3.63%
Quick Ratio3.07%

Price-To-Earnings

Trailing P/E Ratio33.7447774750227
Forward P/E Ratio27.42
P/E Growth1.44

Sales & Book Value

Annual Sales$4.86 billion
Price / Sales8.21
Cash Flow$9.98 per share
Price / Cash37.24
Book Value$41.97 per share
Price / Book8.85

Profitability

Trailing EPS$11.01
Net Income$895.52 million
Net Margins23.17%
Return on Equity25.73%
Return on Assets17.01%

Miscellaneous

Employees5,400
Outstanding Shares107,440,000

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the Zacks' consensus estimate of $3.83 by $0.16. The biopharmaceutical company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company's quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.13 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

When will Regeneron Pharmaceuticals make its next earnings announcement?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Regeneron Pharmaceuticals.

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2018?

25 brokers have issued twelve-month target prices for Regeneron Pharmaceuticals' shares. Their forecasts range from $380.00 to $593.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $471.30 in the next twelve months. View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Regeneron’s third-quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea’s sales. Eylea continues to perform well. Dupixent launch in the United States for moderate-to-severe atopic dermatitis is progressing well. The drug was also approved in Europe. The geographic expansion of the drug will further boost sales. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. The approval of new drugs like Kevzara and Dupixent provide a significant boost to the top-line and reduce the company’s dependence on Eylea for growth. Prospects of PCSK9 inhibitors, a new class of cholesterol-lowering treatments with blockbuster potential, gained instant popularity even before hitting the market. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress payer utilization management restrictions in the United States." (11/14/2017)
  • 2. Canaccord Genuity analysts commented, "Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible." (10/16/2017)
  • 3. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)
  • 4. Cowen Inc analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:

  • P. Roy Vagelos M.D., Chairman of the Board (Age 87)
  • Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director (Age 64)
  • Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance (Age 53)
  • Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply (Age 44)
  • Neil Stahl Ph.D., Executive Vice President - Research and Development (Age 60)
  • Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary (Age 58)
  • Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation (Age 46)
  • Peter Powchik M.D., Senior Vice President - Clinical Development (Age 60)
  • George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director (Age 57)
  • Christopher R. Fenimore, Vice President, Controller (Age 46)

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SANOFI (22.60%), Schwab Charles Investment Management Inc. (0.26%), Bank of Montreal Can (0.18%), National Pension Service (0.07%), DnB Asset Management AS (0.02%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Exxonmobil Investment Management Inc. TX, Nisa Investment Advisors LLC, Gateway Investment Advisers LLC, Livforsakringsbolaget Skandia Omsesidigt and Ingalls & Snyder LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, DnB Asset Management AS, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Fox Run Management L.L.C., National Pension Service, Syntal Capital Partners LLC and Westpac Banking Corp. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $371.53.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $39.92 billion and generates $4.86 billion in revenue each year. The biopharmaceutical company earns $895.52 million in net income (profit) each year or $11.01 on an earnings per share basis. Regeneron Pharmaceuticals employs 5,400 workers across the globe.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 Old Saw Mill River Rd, TARRYTOWN, NY 10591-6717, United States. The biopharmaceutical company can be reached via phone at +1-914-3477000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (REGN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  1,014 (Vote Outperform)
Underperform Votes:  784 (Vote Underperform)
Total Votes:  1,798
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Regeneron Pharmaceuticals (NASDAQ:REGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.362.332.352.42
Ratings Breakdown: 1 Sell Rating(s)
14 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
16 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
13 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
15 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $471.30$464.88$490.17$472.96
Price Target Upside: 25.18% upside20.23% upside11.17% upside8.33% downside

Regeneron Pharmaceuticals (NASDAQ:REGN) Consensus Price Target History

Price Target History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/9/2018CitigroupReiterated RatingNeutral -> Neutral$380.00 -> $388.00HighView Rating Details
12/28/2017ArgusLower Price TargetPositive -> Buy$540.00 -> $470.00LowView Rating Details
12/14/2017Royal Bank of CanadaReiterated RatingHold$430.00LowView Rating Details
12/12/2017Deutsche BankInitiated CoverageHold$397.00MediumView Rating Details
11/28/2017JPMorgan Chase & Co.Reiterated RatingHoldMediumView Rating Details
11/28/2017BTIG ResearchLower Price TargetBuy -> Buy$520.00 -> $480.00LowView Rating Details
11/27/2017BMO Capital MarketsSet Price TargetHold$444.00HighView Rating Details
11/16/2017Evercore ISILower Price TargetOutperform$605.00 -> $445.00N/AView Rating Details
11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/AView Rating Details
11/9/2017Morgan StanleyLower Price TargetEqual Weight$490.00 -> $463.00N/AView Rating Details
11/3/2017Robert W. BairdUpgradeUnderperform -> NeutralN/AView Rating Details
10/23/2017GuggenheimReiterated RatingBuy -> Buy$540.00N/AView Rating Details
10/20/2017BarclaysDowngradeEqual Weight -> Underweight$450.00 -> $395.00N/AView Rating Details
10/16/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
10/6/2017Jefferies GroupReiterated RatingHold$471.00 -> $500.00N/AView Rating Details
10/2/2017SunTrust BanksReiterated RatingHold$435.00MediumView Rating Details
9/27/2017OppenheimerReiterated RatingHoldLowView Rating Details
9/11/2017Credit Suisse GroupReiterated RatingBuy$485.00LowView Rating Details
9/6/2017Raymond James FinancialReiterated RatingOutperform -> Outperform$566.00LowView Rating Details
8/15/2017Leerink SwannReiterated RatingOutperform -> Positive$580.00 -> $552.00LowView Rating Details
8/9/2017Goldman Sachs GroupReiterated RatingNeutral$469.00 -> $472.00LowView Rating Details
7/21/2017Bank of AmericaReiterated RatingBuy$589.00 -> $593.00LowView Rating Details
6/26/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$410.00 -> $480.00LowView Rating Details
5/15/2017CowenReiterated RatingHold$380.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
1/10/2017Wells Fargo & CoReiterated RatingMarket PerformN/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings History and Estimates Chart

Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ REGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018N/AView Earnings Details
11/8/2017Q3 2017$3.83$3.99$1.45 billion$1.50 billionViewN/AView Earnings Details
8/3/2017Q2 2017$2.67$4.17$1.36 billion$1.47 billionViewListenView Earnings Details
5/4/2017Q1 2017$2.50$2.92$1.30 billion$1.32 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.75)($0.68)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.38)($0.49)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.32)($0.17)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.34)($0.41)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.38)($0.31)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.49)($0.38)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.34)($0.46)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.23)($0.01)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.28)($0.19)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.29)($0.22)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.30)($0.40)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.32)($0.27)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.35)($0.22)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.34)($0.15)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.46)($0.19)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings Estimates

Current Year EPS Consensus Estimate: $13.55 EPS
Next Year EPS Consensus Estimate: $14.13 EPS

Dividends

Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Regeneron Pharmaceuticals (NASDAQ REGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.80%
Institutional Ownership Percentage: 66.63%
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ REGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/5/2017Michael S BrownDirectorSell1,500$475.00$712,500.00View SEC Filing  
9/29/2017Charles A BakerDirectorSell2,000$450.00$900,000.0011,000View SEC Filing  
9/6/2017Robert E LandrySVPSell663$498.60$330,571.8010,099View SEC Filing  
9/5/2017Robert E LandryCFOSell189$501.06$94,700.3410,099View SEC Filing  
8/31/2017Robert E LandrySVPSell427$493.43$210,694.619,099View SEC Filing  
8/25/2017SanofiMajor ShareholderBuy72,378$481.36$34,839,874.08View SEC Filing  
8/24/2017SanofiMajor ShareholderBuy166,415$480.93$80,033,965.95View SEC Filing  
8/23/2017Robert E LandrySVPSell468$476.45$222,978.609,099View SEC Filing  
8/22/2017P Roy VagelosChairmanSell56,213$474.48$26,671,944.24363,638View SEC Filing  
8/18/2017P Roy VagelosChairmanSell15,191$470.15$7,142,048.65329,543View SEC Filing  
8/17/2017P Roy VagelosChairmanSell1,305$470.00$613,350.00329,543View SEC Filing  
8/16/2017P Roy VagelosChairmanSell10,986$470.17$5,165,287.62329,543View SEC Filing  
8/8/2017Robert E LandrySVPSell526$472.19$248,371.949,099View SEC Filing  
6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.989,193View SEC Filing  
6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.3043,950View SEC Filing  
6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.003,000View SEC Filing  
6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.9372,043View SEC Filing  
6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.1544,245View SEC Filing  
6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.0014,000View SEC Filing  
6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.8828,477View SEC Filing  
6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50View SEC Filing  
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30414,156View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.003,000View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.001,000View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.0012,000View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.0036,500View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.0015,125View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.0015,125View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.0040,500View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.0111,381View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.0013,000View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.0016,000View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.326,866View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44500,000View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00332,880View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.4522,029View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98351,851View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28543,348View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.009,000View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.1715,441View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.009,000View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.0014,662View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.0014,662View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.0563,102View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.5863,102View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.001,000View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.1615,600View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.2020,029View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.8424,391View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.711,068,343View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.002,000View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.5069,960View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.3625,447View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.9320,742View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00112,772View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.003,000View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.8342,087View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.1665,759View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.0910,736View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.0016,644View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.004,000View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Regeneron Pharmaceuticals (NASDAQ REGN) News Headlines

Source:
DateHeadline
Regeneron Pharmaceuticals Inc (REGN) Receives Average Rating of "Hold" from AnalystsRegeneron Pharmaceuticals Inc (REGN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 10:24 PM
 Analysts Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Post Quarterly Sales of $1.48 Billion Analysts Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Post Quarterly Sales of $1.48 Billion
www.americanbankingnews.com - January 15 at 4:36 AM
Zacks: Analysts Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Post Earnings of $4.65 Per ShareZacks: Analysts Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Post Earnings of $4.65 Per Share
www.americanbankingnews.com - January 13 at 9:36 PM
Cramer's lightning round: People might be bailing on Regeneron, but it's a buyCramer's lightning round: People might be bailing on Regeneron, but it's a buy
finance.yahoo.com - January 12 at 3:18 PM
That Biotech M&A Wave? More like a TrickleThat Biotech M&A Wave? More like a Trickle
finance.yahoo.com - January 12 at 3:18 PM
Cramers lightning round: People might be bailing on Regeneron, but its a buy - CNBCCramer's lightning round: People might be bailing on Regeneron, but it's a buy - CNBC
www.cnbc.com - January 12 at 6:13 AM
Cramer's lightning round: People might be bailing on Rege...Cramer's lightning round: People might be bailing on Rege...
finance.yahoo.com - January 12 at 6:13 AM
Cramers lightning round: People might be bailing on Regeneron, but its a buyCramer's lightning round: People might be bailing on Regeneron, but it's a buy
finance.yahoo.com - January 12 at 6:13 AM
Can Biotech Keep Last Year's Momentum Alive in 2018?Can Biotech Keep Last Year's Momentum Alive in 2018?
finance.yahoo.com - January 11 at 3:19 PM
Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab - NasdaqRegeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab - Nasdaq
www.nasdaq.com - January 10 at 6:36 AM
Regeneron: The Chart Obscures The Progress - Seeking AlphaRegeneron: The Chart Obscures The Progress - Seeking Alpha
seekingalpha.com - January 10 at 6:36 AM
Regeneron CEO talks drug pricing and tax reformRegeneron CEO talks drug pricing and tax reform
finance.yahoo.com - January 10 at 6:36 AM
Finally, a Cure for LegaleseFinally, a Cure for Legalese
finance.yahoo.com - January 9 at 3:18 PM
Rivals Help Fund Regenerons Gene-Sequencing Effort - WSJ - Wall Street JournalRivals Help Fund Regeneron's Gene-Sequencing Effort - WSJ - Wall Street Journal
www.wsj.com - January 9 at 6:52 AM
Regeneron and Sanofi all in with cemiplimab and dupilumab - Seeking AlphaRegeneron and Sanofi all in with cemiplimab and dupilumab - Seeking Alpha
seekingalpha.com - January 9 at 6:52 AM
Rivals Help Fund Regeneron’s Gene-Sequencing EffortRivals Help Fund Regeneron’s Gene-Sequencing Effort
finance.yahoo.com - January 9 at 6:52 AM
Sanofi, Regeneron To Expand Investment For Cemiplimab & Dupilumab DevelopmentSanofi, Regeneron To Expand Investment For Cemiplimab & Dupilumab Development
www.nasdaq.com - January 8 at 11:15 AM
Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available Big Data Human Sequencing Resource with UK BiobankRegeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank
finance.yahoo.com - January 8 at 11:15 AM
Regeneron forms consortium to accelerate gene sequencing projectRegeneron forms consortium to accelerate gene sequencing project
finance.yahoo.com - January 8 at 11:15 AM
Rivals Help Fund Regenerons Gene-Sequencing EffortRivals Help Fund Regeneron's Gene-Sequencing Effort
finance.yahoo.com - January 8 at 11:15 AM
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programsSanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
finance.yahoo.com - January 8 at 11:15 AM
What Are Analysts Saying About Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Future?What Are Analysts Saying About Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Future?
finance.yahoo.com - January 8 at 11:15 AM
Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development ProgramsRegeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs
finance.yahoo.com - January 8 at 11:15 AM
Sanofi and Regeneron boost investment in cancer drug cemiplimabSanofi and Regeneron boost investment in cancer drug cemiplimab
finance.yahoo.com - January 8 at 11:15 AM
Regeneron Regrets: Why Our Higher-Risk Portfolio Underperformed - Seeking AlphaRegeneron Regrets: Why Our Higher-Risk Portfolio Underperformed - Seeking Alpha
seekingalpha.com - January 3 at 11:12 AM
Regeneron Pharmaceuticals Inc (REGN) Expected to Announce Quarterly Sales of $1.48 BillionRegeneron Pharmaceuticals Inc (REGN) Expected to Announce Quarterly Sales of $1.48 Billion
www.americanbankingnews.com - December 30 at 5:40 PM
Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Expensive For A Reason? A Look At The Intrinsic ValueIs Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Expensive For A Reason? A Look At The Intrinsic Value
finance.yahoo.com - December 29 at 9:24 AM
Does Regeneron Pharma Have A Potential Blockbuster In 2018?Does Regeneron Pharma Have A Potential Blockbuster In 2018?
finance.yahoo.com - December 28 at 4:31 PM
Regeneron Pharmaceuticals (REGN) Price Target Cut to $470.00 by Analysts at ArgusRegeneron Pharmaceuticals (REGN) Price Target Cut to $470.00 by Analysts at Argus
www.americanbankingnews.com - December 28 at 9:02 AM
 Analysts Anticipate Regeneron Pharmaceuticals, Inc. (REGN) to Post $4.65 Earnings Per Share Analysts Anticipate Regeneron Pharmaceuticals, Inc. (REGN) to Post $4.65 Earnings Per Share
www.americanbankingnews.com - December 28 at 3:21 AM
$4.65 Earnings Per Share Expected for Regeneron Pharmaceuticals, Inc. (REGN) This Quarter$4.65 Earnings Per Share Expected for Regeneron Pharmaceuticals, Inc. (REGN) This Quarter
www.americanbankingnews.com - December 28 at 3:21 AM
Merus NV (MRUS) Says US Court of Appeals Denies Regenerons (REGN) Petition to Rehear the Panels Decision on ... - StreetInsider.comMerus NV (MRUS) Says US Court of Appeals Denies Regeneron's (REGN) Petition to Rehear the Panel's Decision on ... - StreetInsider.com
www.streetinsider.com - December 27 at 8:07 PM
ETFs with exposure to Regeneron Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Regeneron Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 1:22 PM
Regeneron Pharmaceuticals, Inc. (REGN) Receives Average Recommendation of "Hold" from AnalystsRegeneron Pharmaceuticals, Inc. (REGN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 25 at 5:57 PM
Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 22 at 3:30 PM
Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering - Seeking AlphaYour Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering - Seeking Alpha
seekingalpha.com - December 20 at 6:15 AM
Regeneron in Strategic Immuno-Oncology Collaboration With ISA - NasdaqRegeneron in Strategic Immuno-Oncology Collaboration With ISA - Nasdaq
www.nasdaq.com - December 20 at 6:15 AM
Regeneron, ISA Pharma Announce Strategic Immuno-Oncology CollaborationRegeneron, ISA Pharma Announce Strategic Immuno-Oncology Collaboration
www.nasdaq.com - December 19 at 3:18 PM
ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration - GlobeNewswire (press release)ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration - GlobeNewswire (press release)
www.globenewswire.com - December 18 at 6:24 AM
Regeneron (REGN) Announces Strategic Immuno-Oncology Collaboration with ISA Pharmaceuticals - StreetInsider.comRegeneron (REGN) Announces Strategic Immuno-Oncology Collaboration with ISA Pharmaceuticals - StreetInsider.com
www.streetinsider.com - December 18 at 6:24 AM
ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology CollaborationISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration
finance.yahoo.com - December 18 at 6:24 AM
Cancer Space Update: Roche, Pfizer & Regeneron Make Data PresentationsCancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations
finance.yahoo.com - December 15 at 3:19 PM
Cramer's lightning round: Buy Regeneron, it's not getting...Cramer's lightning round: Buy Regeneron, it's not getting...
finance.yahoo.com - December 15 at 6:18 AM
Cramers lightning round: Buy Regeneron, its not getting the credit it deservesCramer's lightning round: Buy Regeneron, it's not getting the credit it deserves
finance.yahoo.com - December 15 at 6:18 AM
Regeneron (REGN) & Sanofi (SNY) Report Positive Topline Pivotal Results for PD-1 Antibody CemiplimabRegeneron (REGN) & Sanofi (SNY) Report Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab
www.streetinsider.com - December 14 at 3:19 PM
Regeneron’s Dupixent Approved for Atopic DermatitisRegeneron’s Dupixent Approved for Atopic Dermatitis
finance.yahoo.com - December 14 at 3:19 PM
Regeneron’s Kevzara Approved for Treatment of Rheumatoid ArthritisRegeneron’s Kevzara Approved for Treatment of Rheumatoid Arthritis
finance.yahoo.com - December 14 at 3:19 PM
Regeneron Pharmaceuticals (REGN) Earns Hold Rating from Royal Bank of CanadaRegeneron Pharmaceuticals (REGN) Earns Hold Rating from Royal Bank of Canada
www.americanbankingnews.com - December 14 at 8:04 AM
Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering - Seeking AlphaYour Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering - Seeking Alpha
seekingalpha.com - December 14 at 6:24 AM
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares? - Motley FoolWill This Drug Kick-Start Regeneron Pharmaceuticals Shares? - Motley Fool
www.fool.com - December 14 at 6:24 AM

SEC Filings

Regeneron Pharmaceuticals (NASDAQ:REGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Regeneron Pharmaceuticals (NASDAQ:REGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Regeneron Pharmaceuticals (NASDAQ REGN) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.